Mr. Walden (for himself, Mr. Pallone, Mr. Burgess, and Mr. Gene Green of Texas) introduced the following bill; which was referred to the Committee on Energy and Commerce
To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.
Citations are generated automatically from bibliographic data
as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. House. FDA Reauthorization Act of 2017. H.R. 2430. 115th
Cong., 1st
sess., Introduced in House May 16, 2017. https://www.govinfo.gov/app/details/BILLS-115hr2430ih.
APA
Congress, House of Representatives (2017, May 16). FDA Reauthorization Act of 2017 (H.R. 2430 (IH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-115hr2430ih.
MLA
United States, Congress, House of Representatives. FDA Reauthorization Act of 2017. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-115hr2430ih. 115th Congress, H.R. 2430, Introduced in House 16 May. 2017.
Bluebook
H.R.2430 - 115th Congress (2017-2018): FDA Reauthorization Act of 2017, H.R.2430, 115th Cong. (2017), https://www.govinfo.gov/app/details/BILLS-115hr2430ih.
